{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:09:57Z","timestamp":1791875397564,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.blre.2021.100848","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T08:53:04Z","timestamp":1620291184000},"page":"100848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["An owner's manual for CD19 \u201cCAR\u201d-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"50","author":[{"given":"Theodore W.","family":"Laetsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Yanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100848_bb0005","author":"National Cancer Institute Surveillance"},{"key":"10.1016\/j.blre.2021.100848_bb0010","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.bbmt.2016.12.014","article-title":"Disease characteristics and overall survival in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia after stem cell transplantation","volume":"23","author":"Crotta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100848_bb0015","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100848_bb0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100848_bb0025","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2010-07-294678","article-title":"Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children\u2019s Oncology Group","volume":"117","author":"Freyer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/imt-2017-0072","article-title":"CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Liu","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.blre.2021.100848_bb0035","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0040","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2019-129279","volume":"134","author":"Grupp","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0045","first-page":"1280","article-title":"CTL019 therapy appears safe and effective in pediatric patients with Down syndrome with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"130","author":"Laetsch","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0050","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2021.100848_bb0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100848_bb0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0065","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","article-title":"Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS\/combined relapsed\/refractory ALL","volume":"126","author":"Rheingold","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0070","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0075","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-019-0437-5","article-title":"Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL","volume":"33","author":"He","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100848_bb0080","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.1200\/JCO.2020.38.15_suppl.10511","article-title":"CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL)","volume":"38","author":"Newman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0085","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100848_bb0090","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.bbmt.2020.07.036","article-title":"Chimeric antigen receptor T cell therapy in patients with multiply relapsed or refractory extramedullary leukemia","volume":"26","author":"Rubinstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100848_bb0095","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1182\/bloodadvances.2020001450","article-title":"Bilateral retinal detachment after chimeric antigen receptor T-cell therapy","volume":"4","author":"Nagiel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100848_bb0100","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100848_bb0105","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1182\/blood-2019-128262","article-title":"Role of donor-derived CD19.CAR-T cells in treating patients that relapsed after allogeneic hematopoietic stem cell transplantation","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0110","doi-asserted-by":"crossref","first-page":"11471","DOI":"10.2147\/OTT.S277146","article-title":"Low level donor chimerism of CD19 CAR-T cells returned to complete donor chimerism in patients with relapse after allo-hematopoietic stem cell transplant","volume":"13","author":"Li","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.blre.2021.100848_bb0115","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0120","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134472","article-title":"Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: results from the Pediatric Real World CAR Consortium (PRWCC)","volume":"136","author":"Schultz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0130","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100848_bb0135","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2019-130060","article-title":"Cytogenetic characteristics and outcomes of patients receiving CTL019 CAR T cell therapy","volume":"134","author":"Barz Leahy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0140","series-title":"European Hematology Association annual meeting abstract S1618","article-title":"Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities","author":"Grupp","year":"2019"},{"key":"10.1016\/j.blre.2021.100848_bb0145","series-title":"European Hematology Association annual meeting abstract S1565","article-title":"Outcomes of young adult (\u2265 18\u201325 years) and pediatric (<18 years) patients with relapsed\/refractory acute lymphoblastic leukemia following treatment with chimeric antigen receptor (CAR) T-cell therapy","author":"Rives","year":"2018"},{"key":"10.1016\/j.blre.2021.100848_bb0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2141.2011.08846.x","article-title":"Acute lymphoblastic leukaemia in children with Down syndrome: an updated review","volume":"155","author":"Maloney","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100848_bb0155","series-title":"18th annual conference of the Canadian Blood and Marrow Transplant Group. June 7\u20139, 2018; Ottawa, Canada","article-title":"CD19 chimeric antigen receptor T cell therapy in Down syndrome patients with B-cell acute lymphoblastic leukemia","author":"Li","year":"2018"},{"key":"10.1016\/j.blre.2021.100848_bb0160","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.blre.2021.100848_bb0165","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.blre.2021.100848_bb0170","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.blre.2021.100848_bb0175","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100848_bb0180","series-title":"Kymriah (tisagenlecleucel) [package insert]","year":"2018"},{"key":"10.1016\/j.blre.2021.100848_bb0185","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.blre.2021.100848_bb0190","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1182\/blood-2019-127346","article-title":"Tisagenlecleucel manufacturing feasibility in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","volume":"134","author":"Eldjerou","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28155","article-title":"Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia","volume":"67","author":"Shyr","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2021.100848_bb0200","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2021.100848_bb0205","first-page":"S118","article-title":"Tisagenlecleucel for pediatric\/young adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia: preliminary report of B2001X focusing on prior exposure to blinatumomab and inotuzumab","author":"Baruchel","year":"2020","journal-title":"European Hematology Association annual meeting"},{"key":"10.1016\/j.blre.2021.100848_bb0210","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100848_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139260","article-title":"Pre-CAR blinatumomab is associated with increased post-CD19 CAR relapse and decreased event free survival","volume":"136","author":"Taraseviciute","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0220","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100848_bb0225","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2019.37.15_suppl.2520","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL","volume":"37","author":"Perica","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0230","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2018-99-115593","article-title":"High vs. low-intensity bridging chemotherapy in children with acute lymphoblastic leukemia awaiting chimeric antigen receptor T-cell therapy: a population-based study from Ontario, Canada","volume":"132","author":"Gupta","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-018-0164-6","article-title":"The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL","volume":"9","author":"Hucks","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100848_bb0240","doi-asserted-by":"crossref","first-page":"10518","DOI":"10.1200\/JCO.2020.38.15_suppl.10518","article-title":"Tisagenlecleucel (Tisa) for relapsed\/refractory (r\/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO)","volume":"38","author":"Krueger","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0245","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ijrobp.2019.06.514","article-title":"Induction radiation prior to commercial chimeric antigen receptor T-cell therapy for relapsed\/refractory non-Hodgkin lymphoma","volume":"105","author":"LaRiviere","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2021.100848_bb0250","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0255","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0260","doi-asserted-by":"crossref","first-page":"42","DOI":"10.25270\/jcp.2018.10.00039","article-title":"Evolving the delivery of CAR T-cell therapies to the outpatient setting","volume":"4","author":"Smith","year":"2018","journal-title":"J Clin Pathw"},{"key":"10.1016\/j.blre.2021.100848_bb0265","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2021.100848_bb0270","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0275","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100848_bb0280","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V124.21.380.380","article-title":"T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL","volume":"124","author":"Grupp","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0285","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2021.100848_bb0290","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.blre.2021.100848_bb0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2021.100848_bb0305","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0310","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jcyt.2019.04.009","article-title":"Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)","volume":"21","author":"Kadauke","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2021.100848_bb0315","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100848_bb0320","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0325","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.4155\/bio-2019-0192","article-title":"Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis","volume":"11","author":"Fischer","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.blre.2021.100848_bb0330","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100848_bb0335","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100848_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0345","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2021.100848_bb0350","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2021.100848_bb0355","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.blre.2021.100848_bb0360","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","article-title":"Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0365","series-title":"Yescarta (axicabtagene ciloleucel) [package insert]","year":"2019"},{"key":"10.1016\/j.blre.2021.100848_bb0370","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2018-99-115460","article-title":"Molecular detection of minimal residual disease precedes morphological relapse and could be used to identify relapse in pediatric and young adult B-cell acute lymphoblastic leukemia patients treated with tisagenlecleucel","volume":"132","author":"Pulsipher","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0375","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1182\/blood-2019-122195","article-title":"Granulocyte colony-stimulating factor (G-CSF) interactions with chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma","volume":"134","author":"Gaut","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2021.100848_bb0385","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S1470-2045(19)30814-9","article-title":"Immunoglobulin replacement and quality of life after CAR T-cell therapy \u2013 Authors\u2019 reply","volume":"21","author":"Laetsch","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0390","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.bbmt.2017.12.103","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor-T cell therapy for B-cell acute lymphoblastic leukemia","volume":"24","author":"Arnold","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100848_bb0395","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100848_bb0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0405","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100848_bb0410","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1038\/bcj.2011.14","article-title":"Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update","volume":"1","author":"Mohty","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2021.100848_bb0415","first-page":"LBA","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100848_bb0420","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2016.34.15_suppl.3007","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0425","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2021.100848_bb0430","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100848_bb0435","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0440","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1096-911X(200005)34:5<313::AID-MPO1>3.0.CO;2-Q","article-title":"Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia","volume":"34","author":"Leahey","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.blre.2021.100848_bb0445","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100848_bb0450","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:13Z","timestamp":1759436833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":90,"alternative-id":["S0268960X21000540"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100848","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An owner's manual for CD19 \u201cCAR\u201d-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100848"}}